Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Technology Press Releases.
Press releases published on May 12, 2025
Annexon Reports First Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones
GlobeNewswire
·
May 12, 2025
FDA Meeting for Tanruprubart (formerly ANX005), the First Potential Targeted Therapy for GBS, Scheduled for Second Quarter 2025 Ahead of Planned BLA Submission Open-Label Tanruprubart FORWARD Study Designed to Broaden Patient and Healthcare Community …
Quantum BioPharma Announces Completion of Dosing in 90-Day Repeated Dose Oral Toxicity and Toxicokinetic Studies for Lucid-MS for Multiple Sclerosis
GlobeNewswire
·
May 12, 2025
TORONTO, May 12, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today …
Belite Bio to Participate in Four Upcoming Investor Conferences
GlobeNewswire
·
May 12, 2025
SAN DIEGO, May 12, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical …
CervoMed Reports First Quarter 2025 Financial Results and Provides Corporate Updates
GlobeNewswire
·
May 12, 2025
Reported positive 16-week results from the extension phase of the Phase 2b RewinD-LB trial, demonstrating proof-of-concept for neflamapimod as a potential treatment for dementia with Lewy bodies (DLB) Plan to initiate Phase 3 trial of neflamapimod in DLB …
Keros Therapeutics Announces Participation at Bank of America 2025 Global Healthcare Conference
GlobeNewswire
·
May 12, 2025
LEXINGTON, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders …
Tevogen Bio's Business Model Addresses Biopharma Industry Challenges with Cost-Efficient Innovation
GlobeNewswire
·
May 12, 2025
WARREN, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN). As the biopharma industry faces increasing competition from international markets and an evolving regulatory landscape, Tevogen Bio’s …
ORYZON Reports Financial Results and Corporate Update for Quarter Ended March 31, 2025
GlobeNewswire
·
May 12, 2025
Successful completion of €30 Million capital increase, with strong international demand and oversubscription Awarded non-refundable EU grant of €13.26 Million through the first Important Project of Common European Interest (IPCEI) in the health sector ( …
LIS Technologies Inc. Appoints Ryan Norton as its Senior Mechanical Design Engineer
GlobeNewswire
·
May 12, 2025
Oak Ridge, Tennessee, May 12, 2025 (GLOBE NEWSWIRE) -- LIS Technologies Inc. (“LIST” or “the Company”), a proprietary developer of advanced laser technology and the only USA-origin and patented laser uranium enrichment company, today announced that Ryan …
MicroCloud Hologram Inc. Develops Nonlinear Quantum Optimization Technology Based on Efficient Model Encoding
GlobeNewswire
·
May 12, 2025
SHENZHEN, China, May 12, 2025 (GLOBE NEWSWIRE) -- MicroCloud Hologram Inc. (NASDAQ: HOLO), (“HOLO” or the "Company"), a technology service provider, announced the development of a groundbreaking nonlinear quantum optimization algorithm based on efficient …
Bitcoin Crosses The $100K Threshold? ZA Miner Cloud Mining Launches A Simple Bitcoin Mining Solution Allowing Users to Earn BTC Amid the Boom
GlobeNewswire
·
May 12, 2025
London, UK, May 12, 2025 (GLOBE NEWSWIRE) -- Bitcoin rallied sharply on Thursday, 8th May, surpassing the $99k price point as a new bull run promises to break all the 2025 records. According to former BitMex CEO Arthur Hayes, Bitcoin’s rally mirrors what …
ProStar and JAVAD GNSS Announce a Global Partnership to Deliver Precision Mapping Technology to the Utility Industry
GlobeNewswire
·
May 12, 2025
GRAND JUNCTION, Colo., May 12, 2025 (GLOBE NEWSWIRE) -- ProStar® Holdings Inc., (“ProStar®” or “the Company”) (TSXV: MAPS, OTCQX: MAPPF, FSE: 5D00), the developer of the PointMan® Precision Mapping Solutions®, and JAVAD GNSS, the manufacturer of patented …
Alterity Therapeutics Prominently Featured at the International MSA Congress
GlobeNewswire
·
May 12, 2025
– ATH434 Phase 2 data demonstrated clinically meaningful efficacy on multiple clinical endpoints – – MSA Atrophy Index (MSAai) enhances MSA diagnosis and monitoring – – bioMUSE Study shows higher α- synuclein concentration is associated with greater burden …
Aclarion Announces Texas Back Institute as New CLARITY Trial Site
GlobeNewswire
·
May 12, 2025
Texas Back Institute is a world leader in advancing spine technology, science, and education, as well as patient care CLARITY is a randomized clinical trial designed to demonstrate Nociscan’s ability to improve surgical outcomes for chronic low back pain …
SciSparc-Clearmind Collaboration Leads to Publication of European Patent for Psychedelic-Based Combination Therapy for Cocaine Addiction
GlobeNewswire
·
May 12, 2025
TEL AVIV, Israel, May 12, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central …
Clearmind Medicine Announces Publication of European Patent for Psychedelic-Based Combination Therapy for Cocaine Addiction
GlobeNewswire
·
May 12, 2025
Patent publication in Europe strengthens Clearmind’s global IP position and advances strategic focus on addiction treatment Vancouver, Canada, May 12, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company …
BridgeBio to Present Clinical Outcomes, Quality of Life Measures and Incidence of Atrial Fibrillation Events in Patients with ATTR-CM from the ATTRibute-CM Study at the Annual Congress of the Heart Failure Association of the ESC
GlobeNewswire
·
May 12, 2025
PALO ALTO, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced today that one rapid-fire abstract and two moderated …
Abeona Therapeutics® Enters into Agreement to Sell Priority Review Voucher for $155 Million
GlobeNewswire
·
May 12, 2025
CLEVELAND, May 12, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $155 …
Gain Therapeutics Presents Preclinical Data at IAPRD 2025 30th World Congress on Parkinson’s Disease and Related Disorders
GlobeNewswire
·
May 12, 2025
BETHESDA, Md., May 12, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, …
ProMIS Neurosciences Announces First Quarter 2025 Financial Results
GlobeNewswire
·
May 12, 2025
First Cohort Completed in PRECISE-AD Trial Evaluating PMN310 in Alzheimer’s Disease Six Month Interim Results Expected in 1H 2026 Topline Results Anticipated by end of 2026 CAMBRIDGE, Massachusetts, May 12, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences …
Farmasiet, Norway’s largest online pharmacy, signs Agillic for advanced customer engagement
GlobeNewswire
·
May 12, 2025
Press release – Copenhagen, 12 May 2025 – Agillic A/S The Norwegian online pharmacy, Farmasiet, signs Agillic for advanced customer engagement to explore untapped business potential. Farmasiet is Norway's largest online pharmacy, delivering thousands of …